title: Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
abstract: Coexpression of myeloid, B-, and T-lineage associated markers was found in a patient with morphologically and cytochemically undifferentiated acute leukemia. Surface marker analysis using two-color immunofluorescence staining characterized blast cells to express CD34, CD38, CD117, and class II antigens, coexpressing TdT, CD4, CD7, CD13, CD19, and CD33. Cytoplasmic expression of myeloperoxidase, CD3, and CD22 could not be demonstrated. Monosomy for chromosome 7 was found by cytogenetic analysis. The absence of clonal rearrangements of immunoglobulin or T-cell receptor genes was shown by Southern blot analysis. Using a 3H-thymidine incorporation assay, DNA synthesis of leukemic blasts could be stimulated by IL-3, IL-6 and G-CSF in vitro. The present case did not offer specific criteria of lineage commitment. Corresponding to an equivalent counterpart in normal hematopoiesis, the involved cell population may reflect an early, most immature developmental stage within a multipotent progenitor cell compartment.
authors.affiliation: Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Duesseldorf, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Meckenstock
authors.forename: A
authors.initials: A
authors.lastname: Heyll
authors.forename: E M
authors.initials: EM
authors.lastname: Schneider
authors.forename: B
authors.initials: B
authors.lastname: Hildebrandt
authors.forename: V
authors.initials: V
authors.lastname: Runde
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: C R
authors.initials: CR
authors.lastname: Bartram
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: W
authors.initials: W
authors.lastname: Schneider
mesh_terms: D000208:Acute Disease; D015703:Antigens, CD / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D006801:Humans; D016130:Immunophenotyping; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000187:drug effects / Q000473:pathology*; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D014410:Tumor Stem Cell Assay
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D016298:Hematopoietic Cell Growth Factors; D003561:Cytarabine; D008942:Mitoxantrone; D013866:Thioguanine; D003630:Daunorubicin